REQUEST A DEMO
Total
USD $0.00
Search more companies

Immunopharma R&D Sp. z o.o. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Secondary Activities: Construction of Buildings | Pharmaceutical and Medicine Manufacturing | All Other Miscellaneous Chemical Product and Preparation Manufacturing | All Other Professional, Scientific, and Technical Services | Professional Employer Organizations
Full name: Immunopharma R&D Sp. z o.o. Profile Updated: November 21, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Polish Download a sample report

Immunopharma R&D Sp. z o.o. is a company in Poland, with a head office in Krakow. It operates in the Research and Development in Biotechnology (except Nanobiotechnology) industry. The company was established on January 10, 2013. The total number of employees is currently 6 (2013).

Headquarters
Ul. Samuela Bogumila Lindego 7C
Krakow; Malopolskie; Postal Code: 30148

Contact Details: Purchase the Immunopharma R&D Sp. z o.o. report to view the information.

Basic Information
Total Employees:
Purchase the Immunopharma R&D Sp. z o.o. report to view the information.
Outstanding Shares:
Purchase the Immunopharma R&D Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Immunopharma R&D Sp. z o.o. report to view the information.
Incorporation Date:
January 10, 2013
Key Executives
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Immunopharma R&D Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Total equity
0%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?